JPM26: Novartis strengthens neuroscience portfolio with bolt-on deals [Yahoo! Finance]
Avidity Biosciences, Inc. (RNA)
Company Research
Source: Yahoo! Finance
Novartis stated that their capital allocation priorities remain unchanged, and the company will continue to pursue value-creating bolt-on deals to strengthen its pipeline growth. During the presentation, Novartis highlighted more than ten licensed or acquired new molecular entities over the last two years, with neuroscience being one of the key beneficiary therapy areas. During the conference presentation, Novartis noted that the proposed acquisition of Avidity Biosciences would strengthen its neuroscience pipeline and advance RNA therapeutics strategy. The transaction is expected to close in H1 2026 and would add a muscle-targeted RNA delivery platform and three late-stage antibody oligonucleotide conjugate (AOC) RNA neuromuscular programs (del-desiran for myotonic dystrophy type 1, del-brax for facioscapulohumeral muscular dystrophy, and del-zota for Duchenne muscular dystrophy). These three late-stage assets have potential for first-to-market status in their respective diseases a
Show less
Read more
Impact Snapshot
Event Time:
RNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNA alerts
High impacting Avidity Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RNA
News
- SciNeuro and Novartis sign global licensing deal for Alzheimer's antibody [Yahoo! Finance]Yahoo! Finance
- Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Evercore ISI from a "strong-buy" rating to a "hold" rating.MarketBeat
- Avidity Biosciences (NASDAQ:RNA) was given a new $72.00 price target on by analysts at Evercore ISI.MarketBeat
- Assessing Avidity Biosciences (RNA) Valuation After a 130% Year-to-Date Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity [Seeking Alpha]Seeking Alpha
RNA
Earnings
- 11/10/25 - Miss
RNA
Sec Filings
- 1/14/26 - Form DFAN14A
- 1/12/26 - Form DFAN14A
- 1/12/26 - Form DEFA14A
- RNA's page on the SEC website